The Prognosis of Patients After PCI:a Multi-center Study in China
Launched by WUHAN UNION HOSPITAL, CHINA · Nov 6, 2022
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific blood marker called hsCRP (high-sensitivity C-reactive protein) affects the health of patients who have undergone a procedure called percutaneous coronary intervention (PCI) for coronary heart disease (CAD). Researchers believe that measuring hsCRP levels can help understand the risk of serious heart and brain problems after the PCI. The study aims to follow patients for one year to see how changes in hsCRP levels relate to their health outcomes.
To participate in this trial, individuals must be between 18 and 80 years old, have been hospitalized for coronary heart disease, and have completed their PCI procedure. It's important to note that people with certain medical conditions, such as infections, immune diseases, or those who are pregnant, are not eligible to take part. Participants can expect regular check-ins and blood tests over the course of the study to monitor their hsCRP levels and overall health. This research may help improve future care for patients with coronary heart disease in China.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants who understand and sign the informed consent voluntarily;
- • Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
- • The hospitalized patients with coronary heart disease undergoing PCI;
- • Complete all planned PCI during hospitalization.
- Exclusion Criteria:
- • Acute, chronic or recurrent infectious diseases;
- • Immune diseases or immune-related diseases;
- • Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs;
- • Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures;
- • The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.
About Wuhan Union Hospital, China
Wuhan Union Hospital, affiliated with Huazhong University of Science and Technology, is a leading medical institution located in Wuhan, China. Renowned for its comprehensive healthcare services and advanced research capabilities, the hospital plays a pivotal role in clinical trials aimed at enhancing medical knowledge and patient care. With a commitment to innovation and excellence, Wuhan Union Hospital collaborates with various stakeholders to conduct rigorous and ethically sound clinical research, contributing significantly to the advancement of medical science and public health both domestically and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Xiang Cheng, Doctor
Principal Investigator
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials